Check out the latest in PH research news taking place across the globe and right here in Canada: from progress in understanding the science behind PH to developments in early diagnosis, treatment, and improving quality of life. *: Indicates Canadian Research April 16 2021 Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension April 12 2021 Targeted proteomics of right heart adaptation to pulmonary arterial hypertension April 12 2021 Geriatric Nutritional Risk Index Is Associated With Prognosis in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension March 29 2021 Right ventricular adaptation to pressure-overload: Differences between chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension March 22 2021 A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care March 17 2021 Supplementation with Iron in Pulmonary Arterial Hypertension: Two Randomized Crossover Trials March 16 2021 Insights from the Menstrual Cycle in Pulmonary Arterial Hypertension March 11 2021 *Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension March 07 2021 Substantial involvement of TRPM7 inhibition in the therapeutic effect of Ophiocordyceps sinensis on pulmonary hypertension March 06 2021 From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs? March 05 2021 Machine Learning with Contrast-Enhanced CT Can Help Identify Pulmonary Hypertension March 05 2021 The effects of ductal size on the severity of pulmonary hypertension in children with patent ductus arteriosus (PDA): a multi-center study March 02 2021 Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension February 24 2021 Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension February 23 2021 Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits February 22 2021 Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States February 20 2021 Prognostic Value of Early Risk Stratification in Pediatric Pulmonary Arterial Hypertension February 19 2021 Role of pulmonary arterial capacitance in predicting mortality in patients with pulmonary hypertension: A systematic review and meta-analysis February 16 2021 Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study February 15 2021 Serum and Pulmonary Uric Acid in Pulmonary Arterial Hypertension February 10 2021 Pulmonary hypertension in patients with chronic obstructive lung disease: results from COMPERA February 02 2021 Relationship between time from diagnosis and morbidity/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study February 02 2021 Relationship between time from diagnosis and morbidity/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study February 01 2021 The role of genomics and genetics in pulmonary arterial hypertension February 01 2021 The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis January 26 2021 PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation December 16 2020 Pulmonary arterial hypertension associated with congenital heart disease after defect repair: the effect of pregnancy December 10 2020 Longitudinal changes in risk status in pulmonary arterial hypertension December 03 2020 *Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry December 03 2020 Implications of Changing Pulmonary Hypertension Hemodynamic Definitions: Clinician Q&A November 27 2020 Caregiver Burden in Patients with Pulmonary Hypertension November 25 2020 Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with PH November 21 2020 Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in PAH via PI3K/Akt and ERK signaling November 20 2020 At the X-Roads of Sex and Genetics in Pulmonary Arterial Hypertension November 19 2020 Correlation Between Doppler Echocardiography and Right Heart Catheterisation-Derived Systolic and Mean Pulmonary Artery Pressures November 10 2020 Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with PAH October 29 2020 Abnormal Pulmonary Venous Filling: An Adjunct Feature in the Computed Tomography Pulmonary Angiogram Assessment of CTEPH October 29 2020 Evaluation of maternal and fetal outcomes in pregnancy complicated with PAH October 26 2020 CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in CTEPH October 21 2020 Understanding the Psychological Mindset Of People With PAH October 06 2020 BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients October 06 2020 *Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in PAH October 06 2020 Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival October 01 2020 Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric PH September 18 2020 *Limitations and Flaws of Preclinical Pulmonary Hypertension Studies September 18 2020 Novel and Relevant Mechanistic Pathways September 18 2020 Ask the Expert: A Regulatory Perspective on Clinical Trials for PAH September 06 2020 Direct Delivery of MicroRNA96 to the Lungs Reduces Progression of Sugen/Hypoxia-Induced PH August 27 2020 Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model July 22 2020 Impact of concomitant obstructive sleep apnea (OSA) on pulmonary involvement and main pulmonary artery diameter in adults with scleroderma July 14 2020 Adding an important piece to the pulmonary vascular resistance puzzle in PAH July 01 2020 *Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension July 01 2020 Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center July 01 2020 Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable CTEPH June 19 2020 *Queen’s student wins scholarship to continue heart research June 17 2020 Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA June 15 2020 Molecular Profiling of Vascular Remodeling in Chronic Pulmonary Disease June 05 2020 5 Questions About Improving Sleep in PAH June 02 2020 *Use of antihypertensive drugs generates pressure-packed debate in COVID-19 era June 01 2020 Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension May 24 2020 Effects of upper extremity aerobic exercise training on oxygen consumption, exercise capacity, dyspnea and quality of life in patients with pulmonary arterial hypertension May 18 2020 Triple Therapy Beneficial in Treating Pulmonary Arterial Hypertension May 14 2020 Initial Triple vs Double Therapy May Improve Long-Term Outcomes in PAH May 12 2020 Role of Gas6 and TAM Receptors in the Identification of Cardiopulmonary Involvement in Systemic Sclerosis and Scleroderma Spectrum Disorders May 11 2020 Microvesicles and exosomes in pulmonary hypertension May 08 2020 Rapid repurposing of drugs for COVID-19 May 04 2020 PAH Trials Pausing Enrollment for COVID-19, United Therapeutic Says April 30 2020 *Canada leads the world’s first epigenetics treatment trial for pulmonary arterial hypertension April 24 2020 Right Atrial Conduit Phase Emptying Predicts Risk of Adverse Events in Pediatric PAH April 16 2020 Cellular Sources of IL-6 And Associations With Clinical Phenotypes And Outcomes In PAH April 16 2020 Non-invasive vocal biomarker is associated with pulmonary hypertension April 08 2020 Intravascular Ultrasound Pulmonary Artery Denervation to Treat PAH April 05 2020 Incorporation of Renal Function in Mortality Risk Assessment for PAH April 03 2020 Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension March 18 2020 Major Bleed Risk Higher With Warfarin Than Xarelto in CTEPH Patients March 01 2020 Investigational new drug enabling angiotensin oral-delivery studies to attenuate PH March 01 2020 Inspiratory Muscle Training Improves Six-Minute Walk Distance In Adults With Pulmonary Arterial Hypertension February 24 2020 Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension February 07 2020 Advances in Pulmonary Hypertension: Every Picture Tells a Story February 01 2020 Vitamin C Deficiency-Induced Pulmonary Arterial Hypertension December 01 2019 Advances in Pulmonary Hypertension August 07 2019 *PHA Canada Awards Two New Pulmonary Hypertension Research Scholarships May 30 2019 *PAH: First Global Study in Epigenetics to Treat this Disease Real-World Data for Selexipag in Patients With CTD-PAH: A Sphere (Selexipag: A Users Drug Registry) Analysis
April 16 2021 Aryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension
April 12 2021 Geriatric Nutritional Risk Index Is Associated With Prognosis in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
March 29 2021 Right ventricular adaptation to pressure-overload: Differences between chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension
March 22 2021 A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care
March 17 2021 Supplementation with Iron in Pulmonary Arterial Hypertension: Two Randomized Crossover Trials
March 11 2021 *Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension
March 07 2021 Substantial involvement of TRPM7 inhibition in the therapeutic effect of Ophiocordyceps sinensis on pulmonary hypertension
March 06 2021 From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?
March 05 2021 The effects of ductal size on the severity of pulmonary hypertension in children with patent ductus arteriosus (PDA): a multi-center study
March 02 2021 Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension
February 24 2021 Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
February 23 2021 Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits
February 22 2021 Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States
February 20 2021 Prognostic Value of Early Risk Stratification in Pediatric Pulmonary Arterial Hypertension
February 19 2021 Role of pulmonary arterial capacitance in predicting mortality in patients with pulmonary hypertension: A systematic review and meta-analysis
February 16 2021 Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
February 10 2021 Pulmonary hypertension in patients with chronic obstructive lung disease: results from COMPERA
February 02 2021 Relationship between time from diagnosis and morbidity/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study
February 02 2021 Relationship between time from diagnosis and morbidity/mortality in pulmonary arterial hypertension: results from the phase III GRIPHON study
February 01 2021 The prevalence and incidence rate of pulmonary arterial hypertension in systemic sclerosis: Systematic review and meta-analysis
January 26 2021 PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by BMPR2 mutation
December 16 2020 Pulmonary arterial hypertension associated with congenital heart disease after defect repair: the effect of pregnancy
December 03 2020 *Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry
December 03 2020 Implications of Changing Pulmonary Hypertension Hemodynamic Definitions: Clinician Q&A
November 25 2020 Clinical Significance of Guanylate Cyclase Stimulator, Riociguat, on Right Ventricular Functional Improvement in Patients with PH
November 21 2020 Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in PAH via PI3K/Akt and ERK signaling
November 19 2020 Correlation Between Doppler Echocardiography and Right Heart Catheterisation-Derived Systolic and Mean Pulmonary Artery Pressures
November 10 2020 Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with PAH
October 29 2020 Abnormal Pulmonary Venous Filling: An Adjunct Feature in the Computed Tomography Pulmonary Angiogram Assessment of CTEPH
October 26 2020 CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in CTEPH
October 06 2020 BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients
October 06 2020 Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival
September 06 2020 Direct Delivery of MicroRNA96 to the Lungs Reduces Progression of Sugen/Hypoxia-Induced PH
August 27 2020 Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model
July 22 2020 Impact of concomitant obstructive sleep apnea (OSA) on pulmonary involvement and main pulmonary artery diameter in adults with scleroderma
July 01 2020 *Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension
July 01 2020 Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable CTEPH
June 17 2020 Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA
June 01 2020 Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension
May 24 2020 Effects of upper extremity aerobic exercise training on oxygen consumption, exercise capacity, dyspnea and quality of life in patients with pulmonary arterial hypertension
May 12 2020 Role of Gas6 and TAM Receptors in the Identification of Cardiopulmonary Involvement in Systemic Sclerosis and Scleroderma Spectrum Disorders
April 30 2020 *Canada leads the world’s first epigenetics treatment trial for pulmonary arterial hypertension
April 03 2020 Remodeling of active endothelial enhancers is associated with aberrant gene-regulatory networks in pulmonary arterial hypertension
March 01 2020 Inspiratory Muscle Training Improves Six-Minute Walk Distance In Adults With Pulmonary Arterial Hypertension
Real-World Data for Selexipag in Patients With CTD-PAH: A Sphere (Selexipag: A Users Drug Registry) Analysis